Dare Bioscience

Dare Bioscience EBIT CAGR 3Y

The EBIT CAGR (3 Year) of Dare Bioscience (DARE) as of Oct 30, 2026 is -24.42 %. In the previous year, EBIT CAGR (3 Year) was -24.42 % — a change of 0.00% (lower).

EBIT CAGR 3Y

-24.42 %

YoY

0.00%

Last updated:

EBIT CAGR (3 Year) of Dare Bioscience is 2025 -24.42 % . EBIT CAGR (3 Year) of Dare Bioscience was 2024 -24.42 % . It decreases by 0.00% lower compared to the previous year.

The Dare Bioscience EBIT CAGR 3Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 3Y
Date
EBIT CAGR 3Y
Jan 1, 2018
-24.42 USD
Jan 1, 2019
-24.42 USD
Jan 1, 2020
-24.42 USD
Jan 1, 2021
-24.42 USD
Jan 1, 2022
-24.42 USD
Jan 1, 2023
-24.42 USD
Jan 1, 2024
-24.42 USD
Jan 1, 2025
-24.42 USD
The Dare Bioscience EBIT CAGR 3Y history
YEAREBIT CAGR 3YYoY
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %0.00%
-24.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

EBIT CAGR (3 Year) of Dare Bioscience is -24.42 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (3 Year) Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

The 3-year EBIT CAGR shows the compound annual growth rate of EBIT over the past three years.

To evaluate EBIT CAGR (3 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (3 Year).

EBIT CAGR (3 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (3 Year)'s Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Dare Bioscience

All Key Metrics — Dare Bioscience